Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that a systematic approach is crucial to identify causes of androgen excess in women beyond the most common cause, Polycystic ovary syndrome (PCOS).

The research confirms that Hidradenitis Suppurativa is characterized by increased inflammation, disrupted skin cell organization, and abnormal metabolic processes.

Baicalin may help reduce excessive male hormone levels in PCOS.

Prostate cancer can progress even with low testosterone due to internal hormone production in the tumor.

Girls with PCOS have higher levels of certain androgens, which are linked to excess hair growth, but these androgens don't help diagnose PCOS.

Mice without the enzyme HSD17B3 still produce normal testosterone, suggesting they have different ways to make it compared to humans.

Oxidative stress worsens PCOS by damaging cells and disrupting metabolism, suggesting antioxidant treatments might help.

Proteomics combined with other technologies can lead to a better understanding of skin diseases.

Androgens and a high-fat diet may increase the risk of severe COVID-19 in women with PCOS by upregulating certain proteins in the heart and kidneys.

SVF injections improve hair growth and reduce hair loss in people with androgenic alopecia.

Enzymes are classified into six types and are essential for many biological processes, with only a few targeted by drugs.

Multi-omics techniques help understand the molecular causes of androgenetic alopecia.

A substance called Cell-free fat extract can effectively treat common hair loss by increasing hair growth and density.

New treatments for hair loss should target eight main causes and use specific plant compounds and peptides for better results.

A patch with curcumin-zinc can improve hair growth and health by delivering beneficial particles to the skin, increasing hair follicles, and reversing effects of a hair loss hormone.

The research identified genes and non-coding RNAs in cells that could be affected by testosterone, which may help understand hair loss and prostate cancer.

Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.